comparison of efficacy of metacognitive therapy and drug treatment in the frequency and severity of physical symptoms, psychological symptoms and quality of life in patients with functional dyspepsia
Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
A randomized clinical trial study with the control group in Phase 3, including metacognitive, Nortriptyline and control groups with a sample of 65 patients. Sampling at first was available and simple random assignment was used.
A randomized clinical trial study with the control group in Phase 3, including metacognitive, Nortriptyline and control groups with a sample of 160 patients. Sampling at first was available and simple random assignment was used.
A randomized clinical trial study with the control group in Phase 3, including metacognitive, Nortriptyline and control groups with a sample of 65160 patients. Sampling at first was available and simple random assignment was used.
مطالعه کارآزمایی بالینی با گمارش تصادفی دارای گروه کنترل در فاز 3 شامل 3 گروه درمان فراشناختی، نورتریپتیلین و کنترل، حجم نمونه ۶۵ نفر است. نمونه گیری در مرحله اول در دسترس و گمارش تصادفی ساده
مطالعه کارآزمایی بالینی با گمارش تصادفی دارای گروه کنترل در فاز 3 شامل 3 گروه درمان فراشناختی، نورتریپتیلین و کنترل، حجم نمونه 160 نفر است. نمونه گیری در مرحله اول در دسترس و گمارش تصادفی ساده
مطالعه کارآزمایی بالینی با گمارش تصادفی دارای گروه کنترل در فاز 3 شامل 3 گروه درمان فراشناختی، نورتریپتیلین و کنترل، حجم نمونه ۶۵160 نفر است. نمونه گیری در مرحله اول در دسترس و گمارش تصادفی ساده
65 patients with functional dyspepsia were selected during their visit to gastroenterology clinics. After filling consent form, they were randomly assigned to two groups; i.e., drug treatment with Nortriptyline 25 mg and 10 sessions metacognitive psychotherapy. Then, the patients were assessed clinically at pre-/post-treatment and a follow-up after 3 months.
160 patients with functional dyspepsia were selected during their visit to gastroenterology clinics. After filling consent form, they were randomly assigned to two groups; i.e., drug treatment with Nortriptyline 25 mg and 10 sessions metacognitive psychotherapy. Then, the patients were assessed clinically at pre-/post-treatment and a follow-up after 3, 6 months.
65160 patients with functional dyspepsia were selected during their visit to gastroenterology clinics. After filling consent form, they were randomly assigned to two groups; i.e., drug treatment with Nortriptyline 25 mg and 10 sessions metacognitive psychotherapy. Then, the patients were assessed clinically at pre-/post-treatment and a follow-up after 3, 6 months.
تعداد ۶۵ بیمار مبتلا به سوء هاضمه عملکردی مراجعه کننده به کلینیک های گوارش انتخاب شده و بعد از جلب موافقت کتبی به صورت تصادفی در دو گروه درمان دارویی با نورتریپتیلین و روان درمانی فراشناختی ۱۰ جلسه ای قرار میگیرند .سپس در سه مرحله قبل و بعد و ۳ ماه پس از درمانها تحت ارزیابی بالینی و بررسی قرار میگیرند
تعداد 160 بیمار مبتلا به سوء هاضمه عملکردی مراجعه کننده به کلینیک های گوارش انتخاب شده و بعد از جلب موافقت کتبی به صورت تصادفی در دو گروه درمان دارویی با نورتریپتیلین و روان درمانی فراشناختی ۱۰ جلسه ای قرار میگیرند .سپس در سه مرحله قبل و بعد و ۳ و ۶ ماه پس از درمانها تحت ارزیابی بالینی و بررسی قرار میگیرند
تعداد ۶۵160 بیمار مبتلا به سوء هاضمه عملکردی مراجعه کننده به کلینیک های گوارش انتخاب شده و بعد از جلب موافقت کتبی به صورت تصادفی در دو گروه درمان دارویی با نورتریپتیلین و روان درمانی فراشناختی ۱۰ جلسه ای قرار میگیرند .سپس در سه مرحله قبل و بعد و ۳ و ۶ ماه پس از درمانها تحت ارزیابی بالینی و بررسی قرار میگیرند
Intervention group 1: 10-session metacognitive therapy protocol based on anxiety therapy with common medical treatment in control group; Intervention Group 2: Nortriptyline, 25 mg once daily for 10 weeks along with common medical treatment in control group; Control Group: common medical treatment (25 mg omeprazole 25 mg domperidone, both once daily for 10 weeks), diet and regular exercise.
Intervention group 1: 10-session metacognitive therapy protocol based on anxiety therapy with common medical treatment in control group; Intervention Group 2: Nortriptyline, 25 mg once daily for 10 weeks along with common medical treatment in control group; Control Group: common medical treatment (20 mg omeprazole 10 mg domperidone, both once daily for 10 weeks), diet and regular exercise.
Intervention group 1: 10-session metacognitive therapy protocol based on anxiety therapy with common medical treatment in control group; Intervention Group 2: Nortriptyline, 25 mg once daily for 10 weeks along with common medical treatment in control group; Control Group: common medical treatment (2520 mg omeprazole 2510 mg domperidone, both once daily for 10 weeks), diet and regular exercise.
گروه مداخله 1: درمان فراشناختی پروتکل درمانی10 جلسه ای مبتنی بر درمان اضطراب به همراه درمان طبی گروه کنترل ، گروه مداخله 2: درمان نورتریپتیلین 25 میلی گرم یکبار در روز به مدت 10 هفته به همراه درمان طبی گروه کنترل گروه کنترل: درمان طبی (25 میلی گرم امپرازول 25 میلی گرم دمپریدون، هر دو یکبار در روز به مدت 10 هفته) به همراه رعایت رژیم غذایی و ورزش منظم
گروه مداخله 1: درمان فراشناختی پروتکل درمانی10 جلسه ای مبتنی بر درمان اضطراب به همراه درمان طبی گروه کنترل ، گروه مداخله 2: درمان نورتریپتیلین 25 میلی گرم یکبار در روز به مدت 10 هفته به همراه درمان طبی گروه کنترل گروه کنترل: درمان طبی (20 میلی گرم امپرازول 10 میلی گرم دمپریدون، هر دو یکبار در روز به مدت 10 هفته) به همراه رعایت رژیم غذایی و ورزش منظم
گروه مداخله 1: درمان فراشناختی پروتکل درمانی10 جلسه ای مبتنی بر درمان اضطراب به همراه درمان طبی گروه کنترل ، گروه مداخله 2: درمان نورتریپتیلین 25 میلی گرم یکبار در روز به مدت 10 هفته به همراه درمان طبی گروه کنترل گروه کنترل: درمان طبی (2520 میلی گرم امپرازول 2510 میلی گرم دمپریدون، هر دو یکبار در روز به مدت 10 هفته) به همراه رعایت رژیم غذایی و ورزش منظم
General information
65
160
65160
No
No
48
empty
48
2018-02-04, 1396/11/15
empty
2018-02-04 00:00:00
2019-03-06, 1397/12/15
empty
2019-03-06 00:00:00
2019-03-06, 1397/12/15
empty
2019-03-06 00:00:00
empty
the extension of study in order to the sample size and extended follow-ups.
the extension of study in order to the sample size and extended follow-ups.
empty
گسترش مطالعه به دلیل افزایش حجم نمونه و همچنین افزایش مدت جلسات پیگیری
گسترش مطالعه به دلیل افزایش حجم نمونه و همچنین افزایش مدت جلسات پیگیری
Intervention groups
#1
Intervention group 2: 25 mg Nortriptyline for 10 weeks, once daily, Sobhan manufacturer with usual treatment: omeprazole and domperidone 25 mg for 10 weeks, once daily, Sobhan manufacturer, and adhering to recommended diet and regular exercise.
Intervention group 2: 25 mg Nortriptyline for 10 weeks, once daily, Sobhan manufacturer with usual treatment: omeprazole 20 mg and domperidone 10 mg for 10 weeks, once daily, Sobhan manufacturer, and adhering to recommended diet and regular exercise.
Intervention group 2: 25 mg Nortriptyline for 10 weeks, once daily, Sobhan manufacturer with usual treatment: omeprazole 20 mg and domperidone 2510 mg for 10 weeks, once daily, Sobhan manufacturer, and adhering to recommended diet and regular exercise.
گروه مداخله دوم: نورتریپتیلین 25 میلی گرم، به مدت 10 هفته، یک بار در روز، کارخانه سازنده سبحان به همراه درمان رایج طبی معمول امپرازول و دمپریدون 25 میلی گرم به مدت 10 هفته مصرف یکبار در روز و کارخانه سازنده سبحان، و رعایت توصیه های غذایی و ورزش منظم
گروه مداخله دوم: نورتریپتیلین 25 میلی گرم، به مدت 10 هفته، یک بار در روز، کارخانه سازنده سبحان به همراه درمان رایج طبی معمول امپرازول 20 میلی گرم و دمپریدون 10 میلی گرم به مدت 10 هفته مصرف یکبار در روز و کارخانه سازنده سبحان، و رعایت توصیه های غذایی و ورزش منظم
گروه مداخله دوم: نورتریپتیلین 25 میلی گرم، به مدت 10 هفته، یک بار در روز، کارخانه سازنده سبحان به همراه درمان رایج طبی معمول امپرازول 20 میلی گرم و دمپریدون 2510 میلی گرم به مدت 10 هفته مصرف یکبار در روز و کارخانه سازنده سبحان، و رعایت توصیه های غذایی و ورزش منظم
#2
Control group: usual treatment by omeprazole and domperidone 25 mg for 10 weeks, once daily (made by Sobhan company) and adhering to recommended diet and regular exercise.
Control group: usual treatment by omeprazole (20 mg, once daily, Sobhan Darou) and domperidone ( motidon, 10 mg, once daily, Abidi co.) for 10 weeks, and recommended diet and regular exercise.
Control group: usual treatment by omeprazole (20 mg, once daily, Sobhan Darou) and domperidone 25( motidon, 10 mg, once daily, Abidi co.) for 10 weeks, once daily (made by Sobhan company) and adhering to recommended diet and regular exercise.
گروه کنترل: درمان رایج طبی امپرازول و دمپریدون 25 میلی گرم به مدت 10 هفته مصرف یکبار در روز (کارخانه سازنده سبحان) و رعایت توصیه های غذایی و ورزش منظم بوده است
گروه کنترل: درمان رایج طبی امپرازول (۲۰میلی گرم، یکبار در روز، شرکت سبحان دارو) و دمپریدون( موتیدون، ۱۰ میلی گرم، یکبار در روز، شرکت عبیدی) به مدت 10 هفته مصرف یکبار در روز و رعایت توصیه های غذایی و ورزش منظم بوده است
گروه کنترل: درمان رایج طبی امپرازول (۲۰میلی گرم، یکبار در روز، شرکت سبحان دارو) و دمپریدون 25( موتیدون، ۱۰ میلی گرم، یکبار در روز، شرکت عبیدی) به مدت 10 هفته مصرف یکبار در روز (کارخانه سازنده سبحان) و رعایت توصیه های غذایی و ورزش منظم بوده است
Recruitment centers
#1
Name of recruitment center - English: Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences,
Name of recruitment center - Persian: درمانگاه گوارش پژوهشکده گوارش و کبد دانشگاه علوم پزشکی شهید بهشتی
Full name of responsible person - English: Dr.Mohamad Reza Zali
Full name of responsible person - Persian: دکتر محمدرضا زالی
Street address - English: Shahid Beheshti university of medical science, Velenjak st
Street address - Persian: ولنجک، دانشگاه علوم پزشکی شهید بهشتی
City - English: Tehran
City - Persian: تهران
Province: Tehran
Country: Iran (Islamic Republic of)
Postal code: 1985717413
Phone: +98 21 2243 2521
Fax:
Email: info@sbmu.ac.ir
Web page address: http://rigld.sbmu.ac.ir
Name of recruitment center - English: Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences
Name of recruitment center - Persian: درمانگاه گوارش پژوهشکده گوارش و کبد دانشگاه علوم پزشکی شهید بهشتی
Full name of responsible person - English: Dr.Mohamad Reza Zali
Full name of responsible person - Persian: دکتر محمدرضا زالی
Street address - English: Shahid Beheshti university of medical science, Velenjak st
Street address - Persian: ولنجک، دانشگاه علوم پزشکی شهید بهشتی
City - English: Tehran
City - Persian: تهران
Province: Tehran
Country: Iran (Islamic Republic of)
Postal code: 1985717413
Phone: +98 21 2243 2521
Fax:
Email: info@sbmu.ac.ir
Web page address: http://rigld.sbmu.ac.ir
Name of recruitment center - English: Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Name of recruitment center - Persian: درمانگاه گوارش پژوهشکده گوارش و کبد دانشگاه علوم پزشکی شهید بهشتی Full name of responsible person - English: Dr.Mohamad Reza Zali Full name of responsible person - Persian: دکتر محمدرضا زالی Street address - English: Shahid Beheshti university of medical science, Velenjak st Street address - Persian: ولنجک، دانشگاه علوم پزشکی شهید بهشتی City - English: Tehran City - Persian: تهران Province: Tehran Country: Iran (Islamic Republic of) Postal code: 1985717413 Phone: +98 21 2243 2521 Fax: Email: info@sbmu.ac.ir Web page address: http://rigld.sbmu.ac.ir
Sponsors / Funding sources
#1
Name of organization / entity - English:
Name of organization / entity - Persian:
Full name of responsible person - English: Abbas Masjedi Arani
Full name of responsible person - Persian: عباس مسجدی آرانی
Street address - English: Arabi St. Velenjack
Street address - Persian: خیابان اعرابی ولنجک
City - English: Tehran
City - Persian: تهران
Province: Tehran
Country: Iran (Islamic Republic of)
Postal code: 1985717443
Phone: +98 21 23871
Fax:
Email: info@sbmu.ac.ir
Web page address:
Name of organization / entity - English:
Name of organization / entity - Persian:
Full name of responsible person - English: Dr. Afshin Zarghi
Full name of responsible person - Persian: دکتر افشین زرقی
Street address - English: Arabi St. Velenjack
Street address - Persian: خیابان اعرابی ولنجک
City - English: Tehran
City - Persian: تهران
Province: Tehran
Country: Iran (Islamic Republic of)
Postal code: 1985717443
Phone: +98 21 23871
Fax:
Email: info@sbmu.ac.ir
Web page address:
Name of organization / entity - English: Name of organization / entity - Persian: Full name of responsible person - English: Abbas Masjedi AraniDr. Afshin Zarghi Full name of responsible person - Persian: عباس مسجدی آرانیدکتر افشین زرقی Street address - English: Arabi St. Velenjack Street address - Persian: خیابان اعرابی ولنجک City - English: Tehran City - Persian: تهران Province: Tehran Country: Iran (Islamic Republic of) Postal code: 1985717443 Phone: +98 21 23871 Fax: Email: info@sbmu.ac.ir Web page address:
Protocol summary
Study aim
comparing the effect of metacognitive and medication on somatic symptoms, psychological symptoms, and quality of life in functional dyspeptic patient
Design
A randomized clinical trial study with the control group in Phase 3, including metacognitive, Nortriptyline and control groups with a sample of 160 patients. Sampling at first was available and simple random assignment was used.
Settings and conduct
160 patients with functional dyspepsia were selected during their visit to gastroenterology clinics. After filling consent form, they were randomly assigned to two groups; i.e., drug treatment with Nortriptyline 25 mg and 10 sessions metacognitive psychotherapy. Then, the patients were assessed clinically at pre-/post-treatment and a follow-up after 3, 6 months.
Participants/Inclusion and exclusion criteria
The inclusion criteria include: Having functional dyspepsia without comorbid diseases such as IBS or other digestive diseases,
Not having a variety of chronic somatic disease,
Non simultaneous use of other psychiatric drugs,
Non dependency or abusing of substance,
Absence of severe psychiatric disorders,
Age range from 18 to 55,
Having reading and writing skills.
The exclusion criteria include: Unwillingness to participate in the research work for any reason,
The inability of the patient to access the medical center
Patients need to take any medicine other than the prescribed drugs in the study during the study.
Intervention groups
Intervention group 1: 10-session metacognitive therapy protocol based on anxiety therapy with common medical treatment in control group; Intervention Group 2: Nortriptyline, 25 mg once daily for 10 weeks along with common medical treatment in control group; Control Group: common medical treatment (20 mg omeprazole 10 mg domperidone, both once daily for 10 weeks), diet and regular exercise.
Main outcome variables
Functional dyspepsia symptoms, quality of life
General information
Reason for update
the extension of study in order to the sample size and extended follow-ups.
Acronym
IRCT registration information
IRCT registration number:IRCT20190312043036N1
Registration date:2019-10-13, 1398/07/21
Registration timing:retrospective
Last update:2020-01-28, 1398/11/08
Update count:1
Registration date
2019-10-13, 1398/07/21
Registrant information
Name
Sepideh Batebi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 2610 1204
Email address
s.batebi@sbmu.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2019-03-22, 1398/01/02
Expected recruitment end date
2019-08-25, 1398/06/03
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
comparison of efficacy of metacognitive therapy and drug treatment in the frequency and severity of physical symptoms, psychological symptoms and quality of life in patients with functional dyspepsia
Public title
effect of metacognitive therapy on patients with functional dyspepsia
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Having functional dyspepsia without comorbid disease such as IBS or other digestive disease
Not having any variety of chronic somatic diseases
No simultaneous use of other psychiatric drugs
No dependency on or abusing substance
Partial adherence to diet and exercise
Absence of severe psychiatric disorders
Age range between 18 and 55
Having reading and writing skills
Exclusion criteria:
Unwillingness to participate in the research for any reason
Inability of the patient to access the medical center
Having chronic physical impairment or physical inability
Having a severe mental disorder
Substance use or dependence
Patients need to take any medicine other than the prescribed drugs in the study during the study
Age
From 18 years old to 55 years old
Gender
Both
Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size:
160
Randomization (investigator's opinion)
Randomized
Randomization description
At first, the available sample was selected from those who referred to the gastroenterology clinic of Taleghani Hospital and the affiliated centers. Finally, based on the simple random sampling by throwing a dice, the outcomes 1 and 2 were considered for assigning the patients to the metacognitive therapy group, the outcomes 3 and 4 for assigning the patients to the drug treatment group and the outcomes 5 and 6 for the control group.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Shahid Beheshti university of medical science
Street address
Velenjak st
City
Tehran
Province
Tehran
Postal code
1985717443
Approval date
2018-01-16, 1396/10/26
Ethics committee reference number
IR.SBMU.MSP.REC.1396.756
Health conditions studied
1
Description of health condition studied
Functional dyspepsia
ICD-10 code
K30
ICD-10 code description
Functional dyspepsia
Primary outcomes
1
Description
Symptoms of functional dyspepsia
Timepoint
Pre test, post test and follow up
Method of measurement
Leeds dyspepsia questionnaire and clinical interview based on Rome IV
2
Description
depression
Timepoint
Pre test, post test and follow up three months after treatment
Method of measurement
Hamilton depression questionnaire
3
Description
anxiety
Timepoint
Pre test, post test and follow up three months after treatment
Method of measurement
Hamilton anxiety questionnaire
4
Description
quality of life
Timepoint
Pre test, post test and follow up three months after treatment
Method of measurement
Nepean dyspepsia index for quality of life
Secondary outcomes
1
Description
cortisol
Timepoint
Pre test, post test and follow up three months after treatment
Method of measurement
Blood Cortisol Test
2
Description
Emotional regulation
Timepoint
Pre test, post test and follow up three months after treatment
Method of measurement
Questionnaire for difficulty in emotional regulation
3
Description
emotional processing
Timepoint
Pre test, post test and follow up three months after treatment
Method of measurement
Baker's emotional processing questionnaire
Intervention groups
1
Description
Intervention group 1: metacognitive therapy, 10-session 45-minute treatment based on the Adrian Wells protocol approach to metacognitive therapy focused on anxiety protocol; First session: Formulation; Second session: Mindfulness training; Third to sixth sessions: Working on negative metacognitive beliefs; sessions 7 and 8: Challenging Positive metacognitive beliefs; sessions 9 and 10: New processing style training and relapse prevention training with common treatment: omeprazole and domperidone 25 mg for 10 weeks, once daily (made by Sobhan company) plus adhering to recommended diet and regular exercise.
Category
Behavior
2
Description
Intervention group 2: 25 mg Nortriptyline for 10 weeks, once daily, Sobhan manufacturer with usual treatment: omeprazole 20 mg and domperidone 10 mg for 10 weeks, once daily, Sobhan manufacturer, and adhering to recommended diet and regular exercise.
Category
Treatment - Drugs
3
Description
Control group: usual treatment by omeprazole (20 mg, once daily, Sobhan Darou) and domperidone ( motidon, 10 mg, once daily, Abidi co.) for 10 weeks, and recommended diet and regular exercise.
Category
Other
Recruitment centers
1
Recruitment center
Name of recruitment center
Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr.Mohamad Reza Zali
Street address
Shahid Beheshti university of medical science, Velenjak st
City
Tehran
Province
Tehran
Postal code
1985717413
Phone
+98 21 2243 2521
Email
info@sbmu.ac.ir
Web page address
http://rigld.sbmu.ac.ir
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr. Afshin Zarghi
Street address
Arabi St. Velenjack
City
Tehran
Province
Tehran
Postal code
1985717443
Phone
+98 21 23871
Email
info@sbmu.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shahid Beheshti University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
abbas masjedi arani
Position
Assistant professor
Latest degree
Ph.D.
Other areas of specialty/work
Psychology
Street address
Shahid Arababi Street Next to Ayatollah Taleghan Hospital, Yemen St. Martyr Chamran Highway,Tehran
City
Tehran
Province
Tehran
Postal code
1985717443
Phone
+98 21 23871
Email
dr.abbas.masjediarani98@gmail.com
Person responsible for scientific inquiries
Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Abbas Masjedi Arani
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Psychology
Street address
Arabi st. Velenjack
City
Tehran
Province
Tehran
Postal code
1985717443
Phone
+98 21 23871
Email
info@sbmu.ac.ir
Person responsible for updating data
Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Abbas Masjedi Arani
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Psychology
Street address
Arabi St. Velenjack
City
Tehran
Province
Tehran
Postal code
1985717443
Phone
+98 21 23871
Email
info@sbmu.ac.ir
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
results, tables and treatment protocol
When the data will become available and for how long
6 months after publication
To whom data/document is available
Qualified applicants (graduates of medical, specialty and fellowship, psychiatrists, clinical and health psychologists)
Under which criteria data/document could be used
Repeated measure analysis
From where data/document is obtainable
Sepideh Batebi
s.batebi@sbmu.ac.ir
What processes are involved for a request to access data/document
The applicants must first submit their application by an academic email to the correspondent, and then, the requests will be checked within one week and if approved the data will be sent.